Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

HRMY - Harmony Biosciences Holdings Inc


IEX Last Trade
36.005
0.255   0.708%

Share volume: 168,747
Last Updated: Fri 30 Aug 2024 09:59:49 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$35.75
0.26
0.71%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
76%
Profitability 83%
Dept financing 24%
Liquidity 75%
Performance 81%
Company vs Stock growth
vs
Performance
5 Days
-1.05%
1 Month
6.23%
3 Months
24.63%
6 Months
8.18%
1 Year
1.81%
2 Year
-18.54%
Key data
Stock price
$36.00
P/E Ratio 
17.78
DAY RANGE
N/A - N/A
EPS 
$1.96
52 WEEK RANGE
$18.61 - $39.27
52 WEEK CHANGE
-$0.00
MARKET CAP 
2.045 B
YIELD 
N/A
SHARES OUTSTANDING 
56.835 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.35
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$206,806
AVERAGE 30 VOLUME 
$307,443
Company detail
CEO:
Region: US
Website: harmonybiosciences.com
Employees: 221
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.

Recent news